SIRPα- Specific Monoclonal Antibody in China
Name: SIRPα - Specific monoclonal antibody
INDICATIONS: Solid tumors
Hot Tags: sirpα- specific monoclonal antibody, China sirpα- specific monoclonal antibody manufacturers, suppliers, factory, Fulvestrant injection 250mg in 5ml, rhG CSF injection 150 g unit, Enoxaparin Sodium API, rhIL 11 injection 1 5mg, rhIL-11 injection 1.5mg, Recombinant Human Granulocyte Colony-Stimulating Factor
1. Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Website: https://www.jiuyuangene.net/
As a frontrunner in biopharmaceutical development, Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. has established itself as a key player in China's pharmaceutical landscape. With a strong focus on research and innovation, the company specializes in therapeutic proteins, particularly in the fields of hematology and oncology. Its flagship product, a recombinant human granulocyte colony-stimulating factor, is a testament to its advanced bioengineering capabilities. Operating state-of-the-art production facilities that comply with international GMP standards, Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. ensures the highest level of product quality and consistency. The company's commitment to advancing biotech medicines makes it a crucial partner in the global healthcare ecosystem, providing essential treatments to patients worldwide.
2. Biosion, Inc. (Nanjing)
Biosion is a mid-sized clinical-stage biotech company focusing on innovative antibody drugs. Its core asset BSI-082 is a fully human anti-SIRPα monoclonal antibody designed to block the CD47-SIRPα "don't eat me" signal and activate macrophage-mediated phagocytosis. The molecule shows high specificity to multiple SIRPα variants and reduced hematotoxicity compared with CD47-targeting agents. BSI-082 has entered Phase I clinical trials in China, demonstrating favorable safety and preliminary anti-tumor activity. The company's moderate scale, focused pipeline and global development strategy make it a typical medium-sized player in SIRPα antibody research.
3.BioRay Pharmaceutical Co., Ltd.
BioRay is a medium-sized biopharmaceutical firm with a focus on oncology and immunology. Its lead SIRPα antibody BR105 has obtained clinical trial approvals from both NMPA and FDA. The product selectively binds SIRPα and avoids red blood cell interference, showing good safety profiles in preclinical and early clinical studies. It has also been granted orphan drug designation for gastric cancer in the US. The company maintains a lean R&D team and steady clinical progress, positioning itself as a competitive medium-sized enterprise in the SIRPα field without belonging to top pharmaceutical giants.
4.ImmuneOncia Biotech Co., Ltd.
ImmuneOncia is a medium-sized clinical-stage biotech dedicated to CD47-SIRPα pathway therapies. Its flagship product IMM01 is a SIRPα-Fc fusion protein that has advanced to late-stage clinical development. The molecule is engineered to minimize hematotoxicity and potently trigger macrophage phagocytosis. The company also develops bispecific antibodies targeting SIRPα-related pathways for hematological malignancies. With a focused pipeline and efficient clinical operation, ImmuneOncia represents a typical medium-sized player with clear advantages in SIRPα-targeted drugs.
5.Cambrian Biopharma (Suzhou)
Cambrian Biopharma is a medium-sized innovative pharma company engaged in immuno-oncology antibody discovery. It has built a proprietary platform for SIRPα monoclonal antibody development with optimized affinity and selectivity. Its preclinical candidates effectively block CD47 binding and induce tumor cell clearance by macrophages, with improved safety over traditional CD47 antibodies. The company has a professional R&D team and stable financing, maintaining a moderate scale while achieving steady progress in IND-enabling studies.
6.Shanghai Yimai Biopharmaceuticals
Shanghai Yimai is a medium-sized biotech firm focusing on next-generation immune checkpoint antibodies. It has multiple preclinical anti-SIRPα monoclonal antibodies with high specificity and low off-target effects. These candidates avoid cross-reactivity with SIRPγ, reducing immune side effects and showing strong anti-tumor efficacy in animal models. The company's compact R&D system and clear product positioning enable it to maintain efficient development without excessive expansion, fitting the definition of a competitive medium-sized enterprise.
7.Antengene Corporation (Beijing)
Antengene is a medium-sized commercial-stage biopharma company with a strategic layout in SIRPα-related immuno-oncology. It develops novel antibodies that synergize with the CD47-SIRPα axis to reverse tumor immune escape. Its clinical-stage assets demonstrate favorable safety and potential in combination therapies. The company has a balanced pipeline and moderate operational scale, focusing on global clinical development without being an industry giant, making it an important medium-sized participant in SIRPα-targeted therapy.